S. Lagoyko

发表

Flow cytometric minimal residual disease monitoring in children with acute lymphoblastic leukemia treated by regimens with reduced intensity

A. Popov, Y. Y. Verzhbitskaya, G. Tsaur, 2015 .

A simple algorithm with one flow cytometric MRD measurement identifies more than 40% of children with ALL who can be cured with low-intensity therapy. The ALL-MB 2008 trial results

G. Novichkova, N. Ponomareva, M. Belevtsev, 2022, Leukemia.

One-point flow cytometric MRD measurement to identify children with excellent outcome after intermediate-risk BCP-ALL: results of the ALL-MB 2008 study

G. Henze, G. Novichkova, N. Ponomareva, 2022, Journal of Cancer Research and Clinical Oncology.

Low-intensity therapy cures over 40 % of children with rapid Flow-MRD responding ALL: the ALL-MB 2008 trial results

N. Myakova, G. Tsaur, G. Novichkova, 2022, Pediatric Hematology/Oncology and Immunopathology.

A single flow cytometric MRD measurement in children with B-lineage acute lymphocytic leukemia and hyperleukocytosis redefines the requirements of high-risk treatment: Results of the study ALL-MB 2008.

G. Henze, G. Novichkova, N. Ponomareva, 2022, Leukemia research.

High-risk acute lymphoblastic leukemia in the ALL-MB 2002 study

N. Myakova, L. Fechina, G. Novichkova, 2022, Pediatric Hematology/Oncology and Immunopathology.

A hypodiploid karyotype in childhood B-cell precursor acute lymphoblastic leukemia

A. Popov, E. Zerkalenkova, E. Nikitin, 2021, Pediatric Hematology/Oncology and Immunopathology.

Absolute count of leukemic blasts in cerebrospinal fluid as detected by flow cytometry is a relevant prognostic factor in children with acute lymphoblastic leukemia

G. Henze, H. Inaba, A. Popov, 2019, Journal of Cancer Research and Clinical Oncology.

Strong expansion of normal CD19‐negative B‐cell precursors after the use of blinatumomab in the first‐line therapy of acute lymphoblastic leukaemia in children

G. Henze, M. Maschan, G. Novichkova, 2021, British Journal of Haematology.

A simple procedure to identify children with B‐lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single‐point minimal residual disease measurement

G. Henze, G. Novichkova, N. Ponomareva, 2023, Pediatric blood & cancer.

A Single Dose of PEG-Asparaginase at the Beginning of Induction Not Only Accelerates MRD Clearance but Also Improves Long-Term Outcome in Children with B-Lineage ALL

N. Myakova, N. Ponomareva, A. Popov, 2023, Cancers.

The use of blinatumomab in children with de novo Ph-negative B-lineage acute lymphoblastic leukemia and slow clearance of minimal residual disease

G. Tsaur, L. Fechina, G. Novichkova, 2024, Pediatric Hematology/Oncology and Immunopathology.

Bispecific monoclonal antibody blinatumomab in the first-line therapy of B-lineage acute lymphoblastic leukemia in children and adolescents: interim results of the Russian Ministry of Health approbation protocol

G. Novichkova, A. Popov, N. Ponomareva, 2024, Pediatric Hematology/Oncology and Immunopathology.

Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non‐high‐risk acute lymphoblastic leukemia treated according to the ALL‐MB 2008 protocol

N. Ponomareva, N. Miakova, Y. Olshanskaya, 2024, Cancer medicine.

Flow cytometric and cytomorphological definition of remission achievement in children with B-lineage acute lymphoblastic leukemia

L. Fechina, G. Novichkova, A. Popov, 2023, Pediatric Hematology/Oncology and Immunopathology.